Key clinical point: A retrospective study suggests frontline ibrutinib treatment was associated with lower total health care costs, compared with chemoimmunotherapy, in patients with chronic lymphocytic leukemia (CLL).
Major finding: Ibrutinib monotherapy was associated with net monthly cost savings of $3,766, compared with chemoimmunotherapy and bendamustine/rituximab (P less than .0001).
Study details: A claims-based retrospective analysis of 1,161 patients with CLL.
Disclosures: The authors reported financial affiliations with Janssen Scientific Affairs, which funded the study, and other companies.
Emond B et al. Clin Lymphoma Myeloma Leuk. 2019 Aug 26. doi: 10.1016/j.clml.2019.08.004.